治疗非酒精性脂肪性肝病应用熊去氧胆酸的临床效果分析

Analysis of Clinical Effect of Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease

目的对熊去氧胆酸在治疗非酒精性脂肪性肝病的临床疗效进行评价,为指导临床合理用药提供支持。方法随机选取该院2019年9月—2020年8月收治的50例非酒精性脂肪肝患者,所有患者于该院接受临床治疗干预,将其随机分为对照组与观察组,每组25例,对照组使用多烯磷脂酰胆碱胶囊,观察组使用熊去氧胆酸胶囊,观察两组患者谷丙转氨酶(ALT)、谷草转氨酶(AST)和谷氨酰转肽酶(γ-GT)指标变化情况,统计两组临床症状改善情况,比较两组患者治疗效果及生活质量。结果治疗后,观察组患者ALT、AST和γ-GT指标明显改善,与对照组比较差异有统计学意义(t=2.802、2.495、2.330,P<0.05);观察组主要症状(乏力、腹胀、肝区叩击感)发生率为16.00%,与对照组48.00%比较差异有统计学意义(χ^(2)=5.882,P<0.05)。观察组的治疗总有效率高于对照组,且观察组的生活质量优于对照组,差异有统计学意义(P<0.05)。结论熊去氧胆酸在非酒精性脂肪性肝病治疗中效果显著,能降低ALT、AST等肝病生化指标,并且患者临床症状改善明显,提高了患者的生活质量,可对相关治疗方案进行临床推广。

Objective To evaluate the clinical efficacy of ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease,and to provide support for guiding clinical rational drug use.Methods 50 patients with nonalcoholic fatty liver who were admitted to the hospital from September 2019 to August 2020 were randomly selected.All patients received clinical treatment intervention in the hospital,and were randomly divided into control group and observation group,with 25 cases in each group.The control group used polyene phosphatidylcholine capsules,and the observation group used ursodeoxycholic acid capsules.The changes of alanine aminotransferase(ALT),aspartate aminotransferase(AST)and glutamyl transpeptidase(γ-GT)indexes in the two groups were observed,and the improvement of clinical symptoms in the two groups was counted,the treatment effect and the quality of life were compared between the two groups.Results After treatment,the indexes of ALT,AST andγ-GT in the observation group were significantly improved,compared with those in the control group,and the difference was statistically significant(t=2.802,2.495,2.330,P<0.05).The incidence rate of the main symptoms(fatigue,abdominal distension,and percussion in the liver area)in the observation group was 16.00%compared with 48.00%in the control group,the difference was statistically significant(χ^(2)=5.882,P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group,and the quality of life in the observation group was better than that in the control group,the difference was statistically significant(P<0.05).Conclusion Ursodeoxycholic acid has a significant effect in the treatment of non-alcoholic fatty liver disease,can reduce ALT,AST and other biochemical indicators of liver disease,and the clinical symptoms of patients are significantly improved,and the quality of life of patients is improved.Clinical promotion of related treatment programs can be carried out.